Bettina S Frauchiger1, Julia Carlens1,2, Andreas Herger3, Alexander Moeller3, Philipp Latzin1, Kathryn A Ramsey1. 1. Pediatric Respiratory Medicine, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2. Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany. 3. Division of Respiratory Medicine and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Abstract
BACKGROUND: Multiple breath washout (MBW) is increasingly used in the clinical assessment of patients with cystic fibrosis (CF). Guidelines for MBW quality control (QC) were developed primarily for retrospective assessment and central overreading. We assessed whether real-time QC of MBW data during the measurement improves test acceptability in the clinical setting. METHODS: We implemented standardized real-time QC and reporting of MBW data at the time of the measurement in the clinical pediatric lung function laboratory in Bern, Switzerland, in children with CF aged 4-18 years. We assessed MBW test acceptability before (31 tests; 89 trials) and after (32 tests; 96 trials) implementation of real-time QC and compared agreement between reviewers. Further, we assessed the implementation of real-time QC at a secondary center in Zurich, Switzerland. RESULTS: Before the implementation of real-time QC in Bern, only 58% of clinical MBW tests were deemed acceptable following retrospective QC by an experienced reviewer. After the implementation of real-time QC, MBW test acceptability improved to 75% in Bern. In Zurich, after the implementation of real-time QC, test acceptability improved from 38% to 70%. Further, the agreement between MBW operators and an experienced reviewer for test acceptability was 84% in Bern and 93% in Zurich. CONCLUSION: Real-time QC of MBW data at the time of measurement is feasible in the clinical setting and results in improved test acceptability.
BACKGROUND:Multiple breath washout (MBW) is increasingly used in the clinical assessment of patients with cystic fibrosis (CF). Guidelines for MBW quality control (QC) were developed primarily for retrospective assessment and central overreading. We assessed whether real-time QC of MBW data during the measurement improves test acceptability in the clinical setting. METHODS: We implemented standardized real-time QC and reporting of MBW data at the time of the measurement in the clinical pediatric lung function laboratory in Bern, Switzerland, in children with CF aged 4-18 years. We assessed MBW test acceptability before (31 tests; 89 trials) and after (32 tests; 96 trials) implementation of real-time QC and compared agreement between reviewers. Further, we assessed the implementation of real-time QC at a secondary center in Zurich, Switzerland. RESULTS: Before the implementation of real-time QC in Bern, only 58% of clinical MBW tests were deemed acceptable following retrospective QC by an experienced reviewer. After the implementation of real-time QC, MBW test acceptability improved to 75% in Bern. In Zurich, after the implementation of real-time QC, test acceptability improved from 38% to 70%. Further, the agreement between MBW operators and an experienced reviewer for test acceptability was 84% in Bern and 93% in Zurich. CONCLUSION: Real-time QC of MBW data at the time of measurement is feasible in the clinical setting and results in improved test acceptability.
Authors: Sotirios Fouzas; Anne-Christianne Kentgens; Olga Lagiou; Bettina Sarah Frauchiger; Florian Wyler; Ilias Theodorakopoulos; Sophie Yammine; Philipp Latzin Journal: ERJ Open Res Date: 2022-03-14
Authors: Insa Korten; Elisabeth Kieninger; Linn Krueger; Marina Bullo; Christa E Flück; Philipp Latzin; Carmen Casaulta; Claudia Boettcher Journal: Front Pediatr Date: 2022-04-21 Impact factor: 3.569
Authors: Alex R Horsley; John Belcher; Katie Bayfield; Brooke Bianco; Steve Cunningham; Catherine Fullwood; Andrew Jones; Anna Shawcross; Jaclyn A Smith; Anirban Maitra; Francis J Gilchrist Journal: Thorax Date: 2021-07-22 Impact factor: 9.139